7 results
The primary objective is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in subjects receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the subject that best…
Primary Safety Objective * Proportion of patients who complete 24 weeks of combination treatment on pirfenidone at a dose of 1602*2403 mg/d and nintedanib at a dose of 200*300 mg/d Secondary Safety Objective * Proportion of patients who discontinue…
This study will evaluate the efficacy, safety, and tolerability of sildenafil or placebo added to pirfenidone treatment (study treatments) in patients with advanced idiopathic pulmonary fibrosis (IPF) and intermediate or high probability of Group 3…
To study the underlying demographic, clinical and pharmacogenetic factors contributing to the failure of achieving analgesia and/or the occurrence of dose-limiting side effects in individual cancer patients for seperate opioids;- To study if the…
Primary objectiveThe primary objective is to evaluate the effect of Pirfenidone on the change in FEV1 over 6 months in lung transplant recipients with BOS, who are treated with Azithromycin.Secondary objectives The secondary objectives involve the…
The main objective of the trial will be to assess safety and tolerability of combined treatmentwith nintedanib and pirfenidone.A secondary objective is to assess the exposure based on PK trough concentration values tonintedanib either given alone or…
to investigate the safety and tolerability of pirfenidone in asbestosis patients